BOEUF Stock Chart & Stats
$23.30
-$0.92(-4.28%)
At close: 4:00 PM EDT
$23.30
-$0.92(-4.28%)
Day’s Range― - ―
52-Week Range$17.66 - $34.94
Previous CloseN/A
Volume400.00
Average Volume (3M)123.00
Market Cap
$1.52B
Enterprise Value$13.69K
Total Cash (Recent Filing)$434.31M
Total Debt (Recent Filing)$10.13M
Price to Earnings (P/E)68.0
Beta0.46
Next Earnings
Oct 22, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.24
Shares Outstanding65,859,190
10 Day Avg. Volume111
30 Day Avg. Volume123
Financial Highlights & Ratios
PEG Ratio14.80
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio57.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.5
Revenue Forecast (FY)$156.21M
Bulls Say, Bears Say
Bulls Say
High Gross And Operating MarginsSustained gross margins near 92% and mid‑teens to low‑twenties operating margins reflect strong product differentiation and pricing power from a proprietary bioceramic platform. Those margins support reinvestment, scalable profitability and resilience through normal volume cycles.
Strong Cash Generation And ConversionFree cash flow has turned strongly positive and now tracks net income closely, enabling self‑funding of commercial expansion and capital allocation like the SEK 83m buyback. Durable cash generation reduces refinancing risk and improves optionality for R&D and market entry.
Robust U.S. Traction And Product AdoptionFast growth in the U.S. and 40% LTM growth for antibiotic‑eluting CERAMENT indicate strong clinical adoption in a large addressable market. Durable U.S. penetration plus differentiated infection‑management use cases support long‑term volume growth and pricing leverage.
Bears Say
Regulatory And Reimbursement UncertaintyKey near‑term catalysts (De Novo decision for CERAMENT V, CMS reimbursement rule and SOLARIO publication) materially affect addressable use cases and hospital economics. Delays or unfavorable outcomes would slow penetration and could constrain pricing and adoption for months or longer.
Historical Volatility And Turnaround RiskProfitability and cash flow recovery followed earlier losses and volatile results. The business remains exposed to execution risk: sustaining margins and cash conversion relies on continued commercial execution as top‑line growth decelerates from prior hyper‑growth.
Customer Concentration And Operational GatingReliance on several large U.S. accounts creates revenue concentration and operational gating risk: account‑level usage controls can produce quarter‑to‑quarter volatility. Combined with rising commercial incentives, this can pressure near‑term margin durability if adoption stalls.
BONESUPPORT HOLDING AB News
BOEUF FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was $17.66 and its highest was $34.94 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is $1.52B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Oct 22, 2026 which is in 82 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Jul 16, 2026. The company reported $0.128 earnings per share for the quarter, beating the consensus estimate of $0.117 by $0.011.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.14.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of $0.128 in its last earnings report, beating expectations of $0.117. Following the earnings report the stock price went down -6.764%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in BOEUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
BOEUF Company Deck
BOEUF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong revenue growth (30% FX-adjusted), high adjusted margins (29%), solid cash generation and pronounced U.S. launch momentum for CERAMENT G. Material positives include regulatory progress, proposed CMS reimbursement improvements, and healthy EUROW performance. Headwinds include a small set of U.S. accounts temporarily restricting usage (modestly dampening growth), higher commercial and incentive costs, minor gross margin impacts from write-downs and tariffs, and uncertainty around the timing of regulatory approvals and study publications. On balance the company's growth trajectory and scalable profitability outweigh the transitory challenges discussed.View all BOEUF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.49% Mutual Funds
― Other Institutional Investors
86.40% Public Companies and
Individual Investors